Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 8Phase 3 3Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Exercise 216Blood Specimen Collection 122Surveys and Questionnaires 117Standard of Care 114Magnetic Resonance Spectroscopy 113Early Intervention, Educational 108Educational Status 102Methods 101Radiotherapy 94Radiosurgery 76Counseling 72Control Groups 64Biopsy 61Acupuncture Therapy 60Therapeutics 57Psychiatric Rehabilitation 55Resistance Training 53Saline Solution 49Cyclophosphamide 48Palliative Care 46Yoga 41Practice Guidelines as Topic 41Cognitive Behavioral Therapy 41Metformin 40Interviews as Topic 40Drug Therapy 37Surgical Procedures, Operative 36Radiofrequency Ablation 35Dexmedetomidine 35Patient Navigation 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Completed × bosutinib × Clear all
NCT01903733 2022-07-19

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Pfizer

Phase NA Completed
281 enrolled 24 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡